Media stories about AcelRx Pharmaceuticals (NASDAQ:ACRX) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.5888520090032 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

ACRX has been the subject of a number of research reports. Zacks Investment Research raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, May 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.67.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 2.500% during trading on Thursday, hitting $3.075. The company’s stock had a trading volume of 153,094 shares. The company has a 50-day moving average of $2.36 and a 200 day moving average of $2.71. The firm’s market cap is $139.54 million. AcelRx Pharmaceuticals has a one year low of $1.95 and a one year high of $4.08.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. The business had revenue of $3.11 million for the quarter, compared to analyst estimates of $2.36 million. On average, equities analysts forecast that AcelRx Pharmaceuticals will post ($1.15) earnings per share for the current year.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 28.10% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/20/acelrx-pharmaceuticals-nasdaqacrx-receives-media-impact-rating-of-0-15.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.